Drug Topics November 7, 2022
Miranda Hester

Tackling Medicare Part D drug costs takes more than just capping costs.

The current cost sharing structure of Medicare Part D leaves many cancer patients feeling an economic pinch. Most beneficiaries have no limit on out-of-pocket costs and those costs are often calculated as a percentage of the list price instead of fixed copays. A recent editorial published in JAMA Oncology1 addressed the concerns.

With new cancer treatments having out-of-pocket costs of more than $10,000 per year, per drug, costs can quickly add up. A subsidy program exists for low-income Medicare patients, but only around 25% of beneficiaries qualified for this assistance in 2021. By comparison, other programs such as the Affordable Care Act and Tricare have much lower caps...

Today's Sponsors

Transcarent
SalesSparx

Today's Sponsor

Health Edge

 
Topics: Biotechnology, Insurance, Medicare, Pharma, Pharma / Biotech
Top Healthcare Industry Facts for 2023
Inflation Reduction Act Could Cut Medicare Drug Spending by 5%, Study Suggests
States with the largest dual-eligible populations
Smoothing Medicare Part D Out-Of-Pocket Costs Under The Inflation Reduction Act
CMS proposes universal quality measures across all programs

Share This Article